Jewish people in England are being invited to take part in a gene testing programme to identify carriers of BRCA mutations that elevate their risk of breast cancer.
The FDA has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown.
The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.